Synergistic action of first-in-class anti-tropomyosin compound, ATM-3507 (Anisina) and microtubule targeting inhibitors in pre-clinical models of non-small cell lung cancer (NSCLC)

Stehn J.; Mariana A.; Failes T.; Ashokakumar V.; Eiffe E.; Heaton A.; Hook J.; Sivanandhan D.; Arndt G.; Gunning P.; Brown D.

首页> 外文期刊>European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) >Synergistic action of first-in-class anti-tropomyosin compound, ATM-3507 (Anisina) and microtubule targeting inhibitors in pre-clinical models of non-small cell lung cancer (NSCLC)

【24h】

Synergistic action of first-in-class anti-tropomyosin compound, ATM-3507 (Anisina) and microtubule targeting inhibitors in pre-clinical models of non-small cell lung cancer (NSCLC)

机译：一流的抗性对抗性化合物，ATM-3507（Anisina）和微管靶向抑制剂的协同作用，非小细胞肺癌前临床前模型（NSCLC）

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) 》 |2016年第null期| 共1页
作者
Stehn J.; Mariana A.; Failes T.; Ashokakumar V.; Eiffe E.; Heaton A.; Hook J.; Sivanandhan D.; Arndt G.; Gunning P.; Brown D.;
展开▼
作者单位

Novogen ATM Program Sydney NSW Australia;

Childrens Canc Inst ACRF Drug Discovery Ctr Sydney NSW Australia;

Childrens Canc Inst ACRF Drug Discovery Ctr Sydney NSW Australia;

Jubilant Biosys Ltd Bangalore Karnataka India;

Novogen ATM Program Sydney NSW Australia;

Novogen ATM Program Sydney NSW Australia;

UNSW Australia Sch Med Sci Sydney NSW Australia;

Jubilant Biosys Ltd Bangalore Karnataka India;

Childrens Canc Inst ACRF Drug Discovery Ctr Sydney NSW Australia;

UNSW Australia Sch Med Sci Sydney NSW Australia;

Novogen ATM Program Sydney NSW Australia;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学 ;
关键词

相似文献

外文文献
中文文献
专利

1. Synergistic action of first-in-class anti-tropomyosin compound, ATM-3507 (Anisina) and microtubule targeting inhibitors in pre-clinical models of non-small cell lung cancer (NSCLC) [J] . Stehn J., Mariana A., Failes T., European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2016 ,第Null期

机译：一流的抗原肌球蛋白化合物，ATM-3507（Anisina）和微管靶向抑制剂在非小细胞肺癌（NSCLC）临床前模型中的协同作用
2. 49?In situ phenotypic analysis of T cells in the tumor microenvironment of a pre-clinical model of non-small cell lung cancer (NSCLC) by tissue sectioning and whole-mount immunofluorescence imaging [J] . Elen Torres, Stefani Spranger Journal for ImmunoTherapy of Cancer . 2020 ,第Suppla3期

机译：49？在组织切片和全坐埋型免疫荧光成像中非小细胞肺癌（NSCLC）临床前模型T细胞的原位表型分析
3. hsa-miR29b, a critical downstream target of non-canonical Wnt signaling, plays an anti-proliferative role in non-small cell lung cancer cells via targeting MDM2 expression hsa-miR29b, a critical downstream target of non-canonical Wnt signaling, plays an anti-proliferative role in non-small cell lung cancer cells via targeting MDM2 expression hsa-miR29b, a critical downstream target of non-canonical Wnt signaling, plays an anti-proliferative role in non-small cell lung cancer cells via targeting MDM2 expression [J] . Michael G. Edwards, Katherine Vandervest, John Arcaroli, Biology Open . 2013 ,第7期

机译：hsa-miR29b（非经典Wnt信号的关键下游靶标）通过靶向MDM2表达在非小细胞肺癌细胞中发挥抗增殖作用hsa-miR29b（非经典Wnt信号的关键下游靶标）通过靶向MDM2表达在非小细胞肺癌细胞中的抗增殖作用hsa-miR29b（非经典Wnt信号的关键下游靶点）通过靶向MDM2表达在非小细胞肺癌细胞中发挥抗增殖作用
4. Enumeration and ALK Investigation of Circulating Tumor Cells in Non-Small Cell Lung Cancer (NSCLC) Patients Using an Effective In Vivo Technology, the GILUPI CellCollector? [C] . Klaus Luecke, Lukasz Gasiorowski, Stefanie Herold, International Molecular Medicine Tri-Conference. . 2015

机译：使用有效的体内技术（Gilupi Cellcollector
5. 4HPR-X radiation mechanisms of interactions in non-small cell lung cancer (NSCLC) cells in vitro. [D] . Nasca, Melita Maria. 2002

机译：4HPR-X辐射在非小细胞肺癌（NSCLC）细胞中相互作用的体外机制。
6. Tumor-targeted SN38 inhibits growth of early stage non-small cell lung cancer (NSCLC) in a KRas/p53 transgenic mouse model [O] . Alexander Y. Deneka, Leora Haber, Meghan C. Kopp, -1

机译：靶向肿瘤的SN38在KRas / p53转基因小鼠模型中抑制早期非小细胞肺癌（NSCLC）的生长
7. Tumor-targeted SN38 inhibits growth of early stage non-small cell lung cancer (NSCLC) in a KRas/p53 transgenic mouse model. [O] . Alexander Y Deneka, Leora Haber, Meghan C Kopp, 2017

机译：肿瘤靶向sN38抑制KRas / p53转基因小鼠模型中早期非小细胞肺癌（NsCLC）的生长。

Synergistic action of first-in-class anti-tropomyosin compound, ATM-3507 (Anisina) and microtubule targeting inhibitors in pre-clinical models of non-small cell lung cancer (NSCLC)

著录项

相似文献

相关主题

期刊订阅